Related Experiment Video

Updated: May 10, 2026

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

Cytomegalovirus pneumonia in hematopoietic stem cell recipients

Giovanna Travi1, Steven A Pergam2

  • 1Department of Infectious Diseases, AO Ospedale Niguarda Cà Granda, Milan, Italy.

Journal of Intensive Care Medicine
|June 12, 2013
PubMed

Insights

Cytomegalovirus (CMV) pneumonia is a serious risk for stem cell transplant patients. This review covers CMV infection risks, diagnosis, and current and emerging treatments to prevent and manage this complication.

Area of Science:

  • Hematology
  • Infectious Diseases
  • Pulmonology

Background:

  • Cytomegalovirus (CMV) infection is common after hematopoietic cell transplantation (HCT).
  • CMV pneumonia is a severe complication in HCT recipients, leading to significant morbidity and mortality.
  • Understanding CMV pneumonia is crucial for improving patient outcomes post-transplant.

Purpose of the Study:

  • To provide a comprehensive review of Cytomegalovirus (CMV) pneumonia in hematopoietic cell transplantation (HCT) recipients.
  • To discuss the epidemiology, pathogenesis, diagnostics, and current therapeutic strategies for CMV pneumonia.
  • To explore emerging treatment and prevention options for this challenging clinical entity.

Main Methods:

  • Literature review of existing studies on CMV pneumonia in HCT patients.
  • Synthesis of information on epidemiology, pathogenesis, and diagnostic approaches.
  • Analysis of current and emerging therapeutic and prophylactic interventions.

Main Results:

  • CMV pneumonia presents a significant challenge in the post-HCT setting.
  • Early diagnosis and appropriate management are critical for patient survival.
  • Current therapies and preventative strategies are evolving, with new options emerging.

Conclusions:

  • Effective management of CMV pneumonia requires a multi-faceted approach.
  • Continued research into novel treatments and preventative measures is essential.
  • Improving outcomes for HCT recipients with CMV pneumonia remains a key clinical goal.
Keywords:
CMV pneumoniaantiviralcytomegalovirushematopoietic cell transplantprevention

More Related Videos

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Related Concept Videos

Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...